Skip to main content
. 2022 Oct 6;108(6):1530–1543. doi: 10.3324/haematol.2022.280685

Figure 3.

Figure 3.

The presence of ≥0.5 cytomegalovirus-specific CD8+ T cells/mL at 45 days afer hematopoietic stem cell transplantation protects against subsequent clinically relevant events. (A) Receiver operating characteristic analysis for the identification of a protective amount of cytomegalovirus (CMV)-specific CD8+ T cells/mL at 45 days after hematopoietic stem cell transplantation (HSCT). (B) Competitive risk analysis for the risks of clinically relevant events and non-relapse mortality in patients having or not at least 0.5 CMV-specific CD8+ T cells/mL at 45 days after HSCT. (C) Left panel: forest plot showing CRE risk according to the occurrence of acute graft-versus-host disease, host/donor CMV serostatus or the presence of at least 0.5 CMV-specific CD8+ T cells/mL at 45 days after HSCT. Right panel: results of the statistical analysis. The analysis in (B) was performed with the Gray test and that in (C) by logistic regression: *P<0.05. AUC: area under the curve; DEX: Dextramer; aGvHD: acute graft-versus-host disease; OR: odds ratio; CI: confidence interval.